Biotangents

Biotangents is a UK-based biotechnology company specializing in developing diagnostic tests for infectious diseases in livestock. Founded by Dr. Andy Hall-Ponselè and Lina Gasiūnaitė, the company aims to enhance the sustainability and efficiency of traditional industries through genetic technologies. Biotangents leverages advanced molecular techniques, such as machine learning and proprietary algorithms, to design and produce high-performance diagnostic tests that provide quick and accurate results, enabling early disease detection.

In 2016, the company developed modular cell-free nucleic acid detection technology, Moduleic Sensing™, which allows rapid adaptation to various diagnostic needs across livestock industries. Its next-generation molecular diagnostics assay, AmpliSpec™ LAB Mastitis, has been designed to rapidly identify bovine mastitis pathogens, requiring only 70 minutes to deliver results.

Funding and financials

In June 2022, Biotangents secured GBP 2.2 million (~USD 2.7 million), consisting of GBP 1.6 million (~USD 2 million) from the Innovate UK program and GBP 600,000 (~USD 751,600) in venture funding led by Kelvin Capital.